Most recent update: Friday, December 6, 2019 - 09:44

Bariatric News - Cookies & privacy policy

You are here


Apollo reaffirms commitment to bariatric market

Company will ‘rejuvenate’ Lap-Band products

Apollo Endosurgery has reaffirmed its commitment to transforming patient care through the development of innovative, minimally-invasive bariatric and endoscopic surgical solutions, at the 2014 JP Morgan Healthcare Conference.

The company’s President and CEO, Dennis L McWilliams, told investors that the Lap-Band adjustable gastric band and future products to fight the nation’s obesity epidemic are among the company’s priorities in becoming the leader in less invasive solutions for surgeons and patients.

“Apollo Endosurgery is committed to being the leader in providing less invasive solutions for endoscopic and bariatric procedures. Investing in Lap-Band, Orbera and OverStitch products are our immediate priorities,” he said. “We will rejuvenate Lap-Band products because we see that technology as an important weight loss solution for millions of individuals in the future.”

In October 2013, Apollo purchased Allergan’s obesity intervention division for up to US$110 million, which included Lap-Band and the next generation gastric balloon, Orbera products.

With the Lap-Band adjustable gastric band, the company has one of two devices approved by the FDA specifically for weight loss, with a 97 percent global laparoscopic gastric banding market share.

McWilliams said that the Lap-Band product is the only device approved by the FDA to treat lower BMI patients (30 to 35 with one co-morbid condition).

“For many people in the 30 to 35 BMI range, the Lap-Band system is a more viable option than the many diets they’ve tried over and over again without success. It also is the least invasive of the surgical choices available,” he explained.

Apollo has a global share of leading products in two less invasive obesity therapy categories and the company is uniquely situated in that it has crossover growth opportunities in multiple clinical indications beyond bariatrics.

McWilliams stated that Apollo is committed to advancing the Lap-Band system through investments in research that generate additional clinical data, provision of aftercare for patients and consumer education.

The company has completed the integration of the Allergan obesity division sales and marketing personnel into its organisation, and is currently in the process of formulating specific product marketing and development strategies for Lap-Band and Orbera products, as well as obesity market applications utilising the minimally invasive OverStitch endoscopic suturing system.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.

Apollo Endosurgery


Suite 350
7000 Bee Caves Road Austin, TX 78746
United States
30° 18' 6.2388" N, 97° 50' 19.4604" W